Targeting the translational machinery in gastrointestinal stromal tumors (GIST): a new therapeutic vulnerability

Although KIT-mutant GISTs can be effectively treated with tyrosine kinase inhibitors (TKIs), many patients develop resistance to imatinib mesylate (IM) as well as the FDA-approved later-line agents sunitinib, regorafenib and ripretinib. Resistance mechanisms mainly involve secondary mutations in the...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Donna M., Sun, Angela, Patil, Sneha S., Liu, Lijun, Rao, Aparna V., Trent, Parker T., Ali, Areej A., Liu, Catherine, Rausch, Jessica L., Presutti, Laura D., Kaczorowski, Adam, Schneider, Felix, Amankulor, Nduka M., Shuda, Masahiro, Duensing, Anette
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9117308/
https://www.ncbi.nlm.nih.gov/pubmed/35585158
http://dx.doi.org/10.1038/s41598-022-12000-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9117308/
https://www.ncbi.nlm.nih.gov/pubmed/35585158
http://dx.doi.org/10.1038/s41598-022-12000-2

Ejemplares similares